Disposition kinetics of encainide and metabolites.

[1]  T. Shimada,et al.  Human-liver cytochromes P-450 involved in polymorphisms of drug oxidation. , 1986, Xenobiotica; the fate of foreign compounds in biological systems.

[2]  D. Roden,et al.  Co‐inheritance of the polymorphic metabolism of encainide and debrisoquin , 1986, Clinical pharmacology and therapeutics.

[3]  D. Roden,et al.  Spectrum of antiarrhythmic response to encainide. , 1985, The American journal of cardiology.

[4]  R. Shanks,et al.  The Effects of Encainide and Its Major Metabolites,O -Demethyl Encainide and 3-Methoxy-O -Demethyl Encainide, on Experimental Cardiac Arrhythmias in Dogs , 1985, Journal of cardiovascular pharmacology.

[5]  A. K. Dawson,et al.  Differential effects of O-demethyl encainide on induced and spontaneous arrhythmias in the conscious dog. , 1984, The American journal of cardiology.

[6]  A. Gillis,et al.  Myocardial Uptake of Encainide and Its Two Major Metabolites, O‐Demethyl Encainide and 3‐Methoxy‐O‐Demethyl Encainide, in the Dog , 1984, Journal of cardiovascular pharmacology.

[7]  D. Roden,et al.  Influence of genetic polymorphism on the metabolism and disposition of encainide in man. , 1984, The Journal of pharmacology and experimental therapeutics.

[8]  D. Roden,et al.  Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals. , 1984, The Journal of clinical investigation.

[9]  B. Lown,et al.  Encainide for refractory ventricular tachyarrhythmia. , 1983, The American journal of cardiology.

[10]  A. K. Dawson,et al.  Electrophysiologic actions of O-demethyl encainide: an active metabolite. , 1983, Circulation.

[11]  R. Winkle,et al.  Possible contribution of encainide metabolites to the long-term antiarrhythmic efficacy of encainide. , 1983, The American journal of cardiology.

[12]  G. Tucker,et al.  Oxidation phenotype--a major determinant of metoprolol metabolism and response. , 1982, The New England journal of medicine.

[13]  B. Pitt,et al.  Response to Encainide of Refractory Ventricular Tachycardia: Clinical Application of Assays for Parent Drug and Metabolites , 1982, Journal of Cardiovascular Pharmacology.

[14]  D. Roden,et al.  Antiarrhythmic activity of the O-demethyl metabolite of encainide. , 1982, The Journal of pharmacology and experimental therapeutics.

[15]  J. Gottdiener,et al.  Treatment of Frequent Ventricular Arrhythmia with Encainide: Assessment Using Serial Ambulatory Electrocardiograms, Intracardiac Electrophysiologic Studies, Treadmill Exercise Tests, and Radionuclide Cineangiographic Studies , 1982, Circulation.

[16]  R. Winkle,et al.  Metabolite cumulation during long‐term oral encainide administration , 1982, Clinical pharmacology and therapeutics.

[17]  E. Prystowsky,et al.  Electrophysiology of oral encainide. , 1982, The American journal of cardiology.

[18]  D. Zipes,et al.  Effects of encainide and metabolites (MJ14030 and MJ9444) on canine cardiac Purkinje and ventricular fibers. , 1982, The Journal of pharmacology and experimental therapeutics.

[19]  R. Winkle,et al.  Malignant ventricular tachyarrhythmias associated with the use of encainide. , 1981, American heart journal.

[20]  R. Winkle,et al.  Clinical Pharmacology and Antiarrhythmic Efficacy of Encainide in Patients with Chronic Ventricular Arrhythmias , 1981, Circulation.

[21]  F. Peters,et al.  Antiarrhythmic Efficacy of Encainide in Patients with Refractory Recurrent Ventricular Tachycardia , 1981, Circulation.

[22]  D. Roden,et al.  Total suppression of ventricular arrhythmias by encainide. Pharmacokinetic and electrocardiographic characteristics. , 1980, The New England journal of medicine.

[23]  F. Peters,et al.  Clinical electrophysiologic effects of encainide, a newly developed antiarrhythmic agent. , 1979, The American journal of cardiology.

[24]  J. Oates,et al.  Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. , 1978, The New England journal of medicine.

[25]  J. Idle,et al.  Hypotensive response to debrisoquine and hydroxylation phenotype. , 1978, Life sciences.

[26]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[27]  M. Eastwood,et al.  NEUTROPHIL FUNCTION AND MYELOPEROXIDASE ACTIVITY IN INFLAMMATORY BOWEL DISEASE , 1976, The Lancet.